Step Pharma Advances Cancer Treatment Strategies Through Research
Step Pharma, a pioneering company in targeted cancer therapies, is preparing to showcase groundbreaking research on CTPS2-null solid tumors at an esteemed international conference. As the global leader in CTPS1 inhibition, Step Pharma's innovative approach aims to revolutionize cancer treatment methodologies and improve patient outcomes.
Exciting Conference Presentation on Synthetic Lethality
At the upcoming EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, the Chief Scientific Officer, Philip Beer, will present key findings related to synthetic lethality in solid tumors. This research is particularly focused on utilizing AACR Project GENIE data, a critical resource of clinico-genomic information, to identify loss of CTPS2 as a pivotal biomarker. This discovery holds immense potential for selecting specific solid tumors that rely on CTPS1 for survival.
Understanding the Significance of CTPS2
The loss of CTPS2 is a frequent occurrence across various cancer types, especially prevalent in ovarian cancer. This finding is transformative since tumors arising from epithelial tissues are capable of using CTPS1 and CTPS2 in their metabolic pathways. The absence of CTPS2 creates a vulnerability that can be targeted through CTPS1 inhibition, ultimately aiming to halt tumor proliferation.
Precision Oncology Approach with Dencatistat
In light of these insightful findings, Step Pharma is positioning dencatistat, a potent oral CTPS1 inhibitor, at the forefront of their clinical exploration. This compound is currently being assessed in a phase 1a dose escalation study for patients with solid tumors. Notably, there will be safety expansion cohorts specifically for patients with CTPS2-null tumors, beginning with ovarian cancer.
Maximizing Therapeutic Potential
Targeting patients whose tumors have lost CTPS2 exemplifies a precise oncology strategy that optimizes the therapeutic application of dencatistat. This choice aligns with contemporary approaches in personalized medicine, ensuring patients receive treatments tailored to their specific tumor characteristics.
The Role of Advanced Data in Cancer Research
Philip Beer emphasized the significance of analyzing clinico-genomic data, stating, "Our efforts to investigate this data led us to identify promising therapeutic avenues for patients with CTPS2-null solid tumors. With the deletion found in approximately 15-20% of ovarian cancer cases, we are excited about the potential to selectively target cancerous cells through the inhibition of CTPS1. This targeted strategy is a critical advancement in our journey to revolutionize cancer treatment."
About Step Pharma
Founded in 2014, Step Pharma aims to transform the landscape of cancer treatment through innovative targeted therapies that effectively eradicate cancer cells while sparing healthy cells. The company specializes in CTPS1 inhibition, offering the prospect of highly selective, safe, and effective treatments for both hemato-oncological and solid tumors.
Step Pharma, headquartered in Saint-Genis-Pouilly, has garnered support from a robust consortium of investors such as Kurma Partners and V-Bio Ventures. Their mission is supported by the remarkable scientific contributions of renowned figures like Prof. Alain Fischer and Dr. Sylvain Latour. For further information about Step Pharma's innovative work in oncology, visit www.step-ph.com.
Frequently Asked Questions
What is the focus of Step Pharma's upcoming presentation?
Step Pharma will focus on its research concerning CTPS2-null solid tumors and the potential of using dencatistat in treating these cancers.
What role does CTPS2 play in cancer treatment?
CTPS2 is identified as a novel biomarker for certain solid tumors, indicating dependence on CTPS1, which can be targeted for effective treatment.
What is dencatistat?
Dencatistat is an orally available, highly potent inhibitor of CTPS1 currently being studied for its effectiveness against solid tumors.
What percentage of ovarian cancers are associated with CTPS2 deletion?
Approximately 15-20% of ovarian cancers feature the deletion of CTPS2, making it a significant target for precision oncology.
Who is the current Chief Executive Officer of Step Pharma?
The Chief Executive Officer of Step Pharma is Andrew Parker, who leads the company's strategic directions and research initiatives.
